Researchers from Chongqing Medical University have presented data regarding an antiviral compound, KM-10411, derived from a FUBP1 inhibitor (FUBP1-IN-1), as a potential approach to treat hepatitis B virus (HBV) infections.
Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas. Investigators from the National Health Research Institutes have developed a protein-based recombinant vaccine, rHBx-rHBc149, for this unmet medical need.
Farsight Medical Technology (Shanghai) Co. Ltd. has identified cyclosporin analogues found to be potentially useful for the treatment of hepatitis B viral infections.
Researchers from Ospedale San Raffaele presented the preclinical characterization of SR-1891, a long-acting capsid assembly modulator (CAM) in models of chronic hepatitis B. In Hepa D38 cells, the compound exhibited EC50 and EC90 values of 0.2 and 0.8 nM, respectively, without any detectable cytotoxicity.
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most relevant for the novelty it represents and the step forward it signals. The company is investigating the use of TUNE-401 as a potential treatment for hepatitis B.
Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the characterization of ALG-093940, a small molecule PD-1/PD-L1 inhibitor that induces PD-L1 dimerization and degradation.
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense oligonucleotide bepirovirsen.
U.S. Health and Human Services (HHS) Secretary Robert Kennedy made his first stop April 16 on a congressional tour in support of President Donald Trump’s proposed fiscal 2027 budget, which would reduce discretional spending for HHS and its agencies by about 12%.
In one fell swoop March 16, a U.S. federal judge stayed the CDC’s January memo revising the childhood vaccine schedule and the Advisory Committee on Immunization Practices (ACIP) as reconstituted by Health and Human Services Secretary Robert Kennedy, along with everything that committee has done since early June.
Researchers from Model Medicines Inc. have presented preclinical efficacy data for MDL-001, a first-in-class, oral non-nucleoside inhibitor that targets an allosteric site in the Thumb-1 domain of the viral polymerase.
